December 6, 2007 - The first commercial implant of the Mitroflow Aortic Pericardial Heart Valve in the U.S. was performed by the Cardiovascular Surgery Division at Mayo Clinic in Rochester, MN, announced The Sorin Group.
Designed to provide high hemodynamic performance and ease of implant, the Mitroflow valve received FDA approval in October 2007 and is now available to cardiac surgeons and their patients in the U.S.
The first U.S. Mitroflow implant was successfully performed by Rakesh M. Suri, M.D., assistant professor of Cardiac Surgery, Cardiovascular Surgery division, Mayo Clinic, Rochester, MN. Suri said the new valve adds to the tools available for aortic valve implant procedures, and the search for a biological valve prosthesis with durability equal to or better than those existing on the market, with lower gradients, is a sought after goal for all patients.
The Mitroflow valve has the pericardium mounted on the outside of the stent, thus designed to allow for maximum valve opening and optimum blood flow.
The Mitroflow bioprosthesis offers surgeons the option, based on patient anatomy, of a supra-annular or an intra-annular valve placement designed to reduce the risk of patient-prosthesis mismatch and enhance hemodynamic performance.
For more information: www.sorin.com